Patents by Inventor Eric T. Baldwin
Eric T. Baldwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220112179Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.Type: ApplicationFiled: December 20, 2021Publication date: April 14, 2022Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the United States Department of Health and Human Servi, The Regents of the University of CaliforniaInventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer
-
Patent number: 11247985Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.Type: GrantFiled: January 21, 2020Date of Patent: February 15, 2022Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the U.S. Department of Hearth and Human Services, The Regents of the University of CaliforniaInventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer
-
Publication number: 20200157082Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.Type: ApplicationFiled: January 21, 2020Publication date: May 21, 2020Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the United States Department of Health and Human, The Regents of the University of CaliforniaInventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer
-
Patent number: 10633370Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.Type: GrantFiled: October 20, 2016Date of Patent: April 28, 2020Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the U.S. Department of Health and Human Services, The Regents of the University of CaliforniaInventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer
-
Patent number: 10287317Abstract: This invention is related to the field of hypercholesterolemia. In particular, the invention provides compositions and methods to modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9 using synthetic ligands and/or synthetic ligand derivative sequences of 3-8 amino acids ranging between 350-2,000 Da. Altering the conformation of PCSK9 affects the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for ligands which can raise LDL levels.Type: GrantFiled: August 13, 2015Date of Patent: May 14, 2019Assignee: SRX Cardio, LLCInventors: Michael M. Muehlemann, Thomas E. Barta, Kyle D. Monroe, Jonathan William Bourne, Margaret Thompson Reece, Vesa Nevalainen, Eric T. Baldwin
-
Publication number: 20180319778Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.Type: ApplicationFiled: October 20, 2016Publication date: November 8, 2018Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, National Institute of Health, A Component of the U.S Department of Health and Human Services, The Regents of the University of CaliforniaInventors: Donna M. HURYN, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neilz, Kean-Hooi Ang, Cliffford Bryant, Stacie Bulfer
-
Publication number: 20170210799Abstract: Provided herein are isolated antibodies that immunospecifically bind to ROR1, bispecific antibodies comprising an antigen-binding site that immunospecifically binds to ROR1 and an antigen-binding site that immunospecifically binds to CD3, and methods of using the same.Type: ApplicationFiled: January 19, 2017Publication date: July 27, 2017Inventors: Glenn Mark ANDERSON, Eric T. BALDWIN, Benjamin HARMAN, Rosa M.F. CARDOSO, Jennifer F. NEMETH-SEAY, Ricardo ATTAR, Francois GAUDET, Yingzhe LI, Jinquan LUO, Ronan MCDAID, Steven C. POMERANTZ, Susan H. TAM, Alexey TEPLYAKOV, Sheng-Jiun WU
-
Publication number: 20160083425Abstract: This invention is related to the field of hypercholesterolemia. In particular, the invention provides compositions and methods to modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9 using synthetic ligands and/or synthetic ligand derivative sequences of 3-8 amino acids ranging between 350-2,000 Da. Altering the conformation of PCSK9 affects the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for ligands which can raise LDL levels.Type: ApplicationFiled: August 13, 2015Publication date: March 24, 2016Inventors: Michael M. Muehlemann, Thomas E. Barta, Kyle D. Monroe, Jonathan William Bourne, Margaret Thompson Reece, Vesa Nevalainen, Eric T. Baldwin
-
Publication number: 20140011700Abstract: The binding mode of the antiviral compounds have been characterized through a variety of biophysical and structural studies, elaborating on the proposed aggregation mechanism of action. We demonstrate the direct binding of these antiviral compounds to NP using thermal shift enhancement assay (TSE) and NMR. In addition, we have completed a detailed analysis of the oligomerization mechanism of action using dynamic light scattering, analytical ultracentrifugation, and surface plasmon resonance (SPR). Structure determination using x-ray crystallography confirmed the proposed compound-induced oligomerization mechanism of action. The co-crystal structure revealed that two compounds bound in an anti-parallel fashion bridging two NP monomers, inducing a novel non-native NP oligomer.Type: ApplicationFiled: March 23, 2012Publication date: January 9, 2014Inventors: Eric T. Baldwin, Patricia Ann McDonnell, Suzanne Edavettal, Hal Lewis, Bradley C. Pearce, David R. Langley, Christopher W. Cianci, Linda Discotto, Samuel Gerritz, Shuhao Shi, Shirong Zhu
-
Publication number: 20100145056Abstract: Disclosed are compounds of the formula: where variables Z, X, R15, R2, R3, and Rc are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.Type: ApplicationFiled: November 23, 2009Publication date: June 10, 2010Inventors: Varghese John, Michel Maillard, James P. Beck, Eric T. Baldwin, Robert Hughes, Shon R. Pulley, Ruth T. TenBrink
-
Patent number: 7645780Abstract: Disclosed are compounds of the formula: where variables Z, X, R15, R2, R3, and Rc are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.Type: GrantFiled: June 6, 2006Date of Patent: January 12, 2010Assignee: Elan Pharmaceuticals, Inc.Inventors: Varghese John, Michel Maillard, James P. Beck, Eric T. Baldwin, Robert Hughes, Shon R. Pulley, Ruth T. TenBrink
-
Patent number: 7244725Abstract: Disclosed are compounds of the formula: where variables Z, X, R15, R2, R3, and RC are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.Type: GrantFiled: September 10, 2003Date of Patent: July 17, 2007Assignees: Elan Pharmaceuticals, Inc., Pharmacia & Upjohn CompanyInventors: Varghese John, Michel Maillard, James P. Beck, Eric T. Baldwin, Robert Hughes, Shon R. Pulley, Ruth TenBrink
-
Patent number: 6864080Abstract: Staphylococcus aureus peptide deformylase has been crystallized, and the three-dimensional x-ray crystal structure has been solved to 1.9 ? resolution. The x-ray crystal structure is useful for solving the structure of other molecules or molecular complexes, and designing modifiers of peptide deformylase activity.Type: GrantFiled: June 29, 2001Date of Patent: March 8, 2005Assignee: Pharmacia & Upjohn CompanyInventors: Eric T. Baldwin, Melissa S. Harris
-
Publication number: 20040202644Abstract: Staphylococcus aureus peptide deformylase has been crystallized, and the three-dimensional x-ray crystal structure has been solved to 1.9 Å resolution. The x-ray crystal structure is useful for solving the structure of other molecules or molecular complexes, and designing modifiers of peptide deformylase activity.Type: ApplicationFiled: January 10, 2003Publication date: October 14, 2004Inventors: Eric T. Baldwin, Melissa S. Harris
-
Publication number: 20040180939Abstract: Disclosed are compounds of the formula: 1Type: ApplicationFiled: September 10, 2003Publication date: September 16, 2004Inventors: Varghese John, Michel Maillard, James P. Beck, Eric T. Baldwin, Robert Hughes, Shon R. Pulley, Ruth TenBrink
-
Publication number: 20040126809Abstract: Hepatitis C virus helicase has been crystallized as tetragonal and orthorhombic crystals, and the structures of the crystals has been solved. The structure coordinates of the crystal structures are useful for solving the structures of other molecules or molecular complexes.Type: ApplicationFiled: May 2, 2001Publication date: July 1, 2004Inventors: Barry C. Finzel, Melissa S. Harris, Eric T. Baldwin
-
Publication number: 20030170868Abstract: Staphylococcus aureus peptide deformylase has been crystallized, and the three-dimensional x-ray crystal structure has been solved to 1.9 Å resolution. The x-ray crystal structure is useful for solving the structure of other molecules or molecular complexes, and designing modifiers of peptide deformylase activity.Type: ApplicationFiled: June 29, 2001Publication date: September 11, 2003Inventors: Eric T. Baldwin, Melissa S. Harris
-
Publication number: 20030165984Abstract: Hepatitis C virus helicase has been crystallized as tetragonal and orthorhombic crystals, and the structures of the crystals has been solved. The structure coordinates of the crystal structures are useful for solving the structures of other molecules or molecular complexes.Type: ApplicationFiled: May 2, 2001Publication date: September 4, 2003Inventors: Barry C. Finzel, Melissa S. Harris, Eric T. Baldwin